Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Number of Employees Founded (year) Type of Laboratory Areas of Activity
Request for Further Collaborations
›
› › › › › › › › › › ›
›
›
UGA Biopharma GmbH Neuendorfstr. 20a 16761 Hennigsdorf Germany Sylwia Naamane +49-3302-2024-900 +49-3302-2024-901 info@ugabiopharma.com www.ugabiopharma.com 40 2009 S1 | Cell Line Development Services | New Biological Drug Development | Biosimilar Development | Ready-to-Use Biosimilar Cell Lines | Cell Culture Media and Feeds UGA Biopharma is seeking | Strategic partnerships for upscaling and GMP manufacturing | Collaboration for development of NBEs or biosimilars | Cooperation partners for in-licensing our Ready-to-Use Biosimilar Cell Lines We would be happy to discuss your request.
UGA Biopharma is an expert in the area of developing mammalian cell lines for biopharmaceutical products. We offer customised cell line development services for new biological entities (NBEs) and biosimilars. UGA’s mission is to deliver high-end contract services that satisfy and exceed customer expectations. With our dedication to constantly improving our operations, we see ourselves as a reputable and prosperous player known for quality and reliability.
Customised Cell Line Development Services UGA Biopharma is the right partner for industry and academia when it comes to the development of cell lines expressing biologics for clinical trials and market access. We guarantee consistently high quality and full traceability of Cell Line Development activities. Our proprietary approach for success is a combination of host cell line, optimised expression vector, and high performance First CHOice® medium and feeds. Unique and long lasting expertise in cell line development, bioprocess optimisation, downstream processing, and analytics complete our services.
Ready to Use Biosimilar Cell Lines* Biologics are one of the most cost-intensive treatments on the global market today, which implies the need for low-cost alternatives. UGA has gained its expert knowledge by developing biosimilar cell lines for twelve years now. UGA ensures high analytical biosimilarity by balancing clone choice, USP process, and DSP development carefully for each biosimilar. Besides developing a biosimilar cell line on request, we promote a broad spectrum of Ready to Use Biosimilar Cell Lines, including documentation, which are ready to out-license to a collaboration partner: › Adalimumab › Bevacizumab › Mepolizumab › Nivolumab › Omalizumab › Trastuzumab
